Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

Antibodies that target the immune checkpoint receptor programmed cell death protein 1 (PD-1) have resulted in prolonged and beneficial responses toward a variety of human cancers. However, anti–PD-1 therapy in some patients provides no benefit and/or results in adverse side effects. The factors that...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Invest
Autori principali: Mehnert, Janice M., Panda, Anshuman, Zhong, Hua, Hirshfield, Kim, Damare, Sherri, Lane, Katherine, Sokol, Levi, Stein, Mark N., Rodriguez-Rodriquez, Lorna, Kaufman, Howard L., Ali, Siraj, Ross, Jeffrey S., Pavlick, Dean C., Bhanot, Gyan, White, Eileen P., DiPaola, Robert S., Lovell, Ann, Cheng, Jonathan, Ganesan, Shridar
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2016
Soggetti:
Brief Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4887167/
https://ncbi.nlm.nih.gov/pubmed/27159395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI84940
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi